The main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with IT resistance through the constitution of a collection associating blood or marrow samples from patients with LA, MDS and MPS marrow samples from patients with LA, MDS and MPS at diagnosis, during treatment and at relapse and relapse and clinical annotations.
Diagnosis of acute leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) or myeloproliferative syndrome according to the WHO classification 2016,
Patient for whom a new line of therapy is initiated.
Patient older than 18 years of age.
Patient affiliated to the social security system or benefiting from such a system.
Weight at inclusion < 50 kg
Participating in another clinical study that would cause the total amount of blood collection to exceed the and endanger the patient
Person in an emergency situation, adult under legal protection (guardianship, curatorship, etc.) protection (guardianship, curatorship or safeguard of justice), or unable to express his or her consent.
Impossibility to submit to the medical follow-up of the trial for geographical social or psychological reasons,